Herpes zoster: The disease and the vaccines Tony Cunningham Centre for Virus Research The Westmead Institute for Medical Research Sydney, Australia
|
|
- Polly Perry
- 6 years ago
- Views:
Transcription
1 Herpes zoster: The disease and the vaccines Tony Cunningham Centre for Virus Research The Westmead Institute for Medical Research Sydney, Australia Declarations Chair, Publications committee, GSK Shingrix ZoE50 and ZoE70 trials Member, Global Adult Vaccine Advisory Board, Merck Chair, Zostaxax Advisory Board, BioCSL 1
2 Herpes Zoster (shingles) Reactivation of latent varicella zoster virus Markedly increases after 50 years Usually unilateral, vesicular cutaneous eruption with a dermatomal distribution Acute pain accompanies the rash in >90% of individuals aged over 50 years The most common complication is post herpetic neuralgia (PHN), defined as pain persisting for 90 or more days after rash onset >50% of population >85 years will get zoster Gnann, Jr. & Whitley 2002 Dworkin et al Age dependent incidence of herpes zoster and PHN in Australia Stein A et al Vaccine
3 0 0 7/15/2016 Neurologic Cutaneous Ocular Involvement Rate of HZ Complications Sacral Dermatome Involvement Visceral Complications n 298 ZOSTAVAX N=19, Incidence Rate* n Placebo N=19, Incidence Rate* *Incidence rate= per 1000 person years (total population). Incidence of Herpes zoster is increasing globally Trend in zoster ED visits - NSW Non-Admitted Admitted NSW Admitted ED Visits per 100,000 population Year Year <25 <25 predicted predicted <25 <25 predicted predicted predicted predicted predicted predicted predicted predicted predicted predicted Rates of ED visits increased with age. Most ED visits are not admitted Increasing trend in non-admitted ED visits over time, most prominent in older population) MacIntyre R et al Plos One
4 RCF (per 100,000 PBMC) 7/15/2016 Types of vaccines Whole virus Live attenuated Inactivated Split Sub-unit Rationale for a HZ Vaccine The frequency and severity of zoster increase with age T cell responses to VZV decline with aging, while antibody does not The basis for two hypotheses: >8 Age (years) 5 1. the fall in T cell responses to VZV with age to below a threshold permits clinical reactivation of latent VZV 2. increasing the T cell responses to VZV in older people will prevent OR attenuate herpes zoster 4
5 Pilot studies of HZ Vaccine Pilot studies demonstrated that T cell responses to VZV could be safely boosted with a live attenuated Oka strain VZV These studies suggested that the booster effect was significantly increased for 6 years Levin M et al J.Infect Dis 2003 Shingles Prevention Study (SPS) A double-blind, placebo-controlled trial 22 Sites Live, attenuated VZV vaccine Oka/Merck strain (Median = 24,600 pfu) 14-fold greater titer than childhood vaccine Subjects = 38,500 Median age = 69 years years = 20, years = 17,800 (46%) years = ~2500 (>6.5%) Oxman al. NEJM 352; 2271:
6 Worst pain score 7/15/2016 SPS: Endpoints Herpes Zoster (incidence/1000/year) Mean follow-up = 3.13 years Burden of Illness (BOI) Sum of all severity of illness scores for each of two treatment groups - vaccinees and placebo recipients (No HZ = score of 0) Post-herpetic neuralgia (PHN) Significant pain ( 3 on ZBPI) 90 days after rash onset 95% of subjects completed the study AUC of Worst Pain Scores Over Time Days since rash onset 6
7 Incidence of HZ 7/15/2016 SPS: Efficacy HZ Incidence 51.3% ( %) Burden Of Illness 61.1% ( %) Post Herpetic Neuralgia 66.5% ( %) 13 Vaccine Efficacy for Incidence of Herpes Zoster Efficacy (95% CI) % ( ) 63.9% 37.6% Vaccine Placebo 0 All yr 70 yr 7
8 Incidence of PHN HZ burden of illness 7/15/2016 Vaccine Efficacy for Herpes Zoster BOI Efficacy (95% CI) 61.1% ( ) 65.5% ( ) 55.4% ( ) Vaccine Placebo All yr 70 yr Vaccine Efficacy for Incidence of PHN Efficacy (95% CI) 66.5% ( ) 65.7% ( ) 66.8% ( ) Vaccine Placebo All Subjects yr 70 yr 8
9 SPS: Conclusions In the full SPS population Zostavax significantly altered the natural history of zoster Prevented zoster in the younger group of vaccinees (60-69) Prevented OR attenuated zoster in the older group of vaccinees (>70) Efficacy and safety essentially replicated in several large postmarketing studies (Kaiser Permanente, CA etc) Low rates of severe injection site reactions (~1%) SPS ZEST Study in year olds: HZ incidence decreased by 70%, HZ pain by 73% (ie greater VE) Duration of protection of Zostavax Short term Persistence Substudy: Zostavax /6950 placebo recipients, 89% of which accepted the offer of Zostavax; all participants followed for 4-7 years - VE = 39.6% for zoster, 60% for phn and 50% for BOI Long term Persistence Substudy - Open label Multicentre study, followed up 6867 vaccine recipients for 7-12 years. No unvaccinated concurrent control group so original SPS placebo recipients used as controls. - VE = 21% for zoster, 35% for PHN and 37% for BOI - ie provides evidence for waning of efficacy but probably significant to 8 years when analysed annually Booster dose at 10 years: in >70 year old CMI responses were stimulated to levels similar to those of a first response in YO (Levin M et al JID 2016) 9
10 Effectiveness and 95% confidence interval of herpes zoster vaccine, by years after vaccination, Kaiser Permanente Southern California, Hung Fu Tseng et al. J Infect Dis. 2016;213: Zoster vaccines for Immunecompromised patients Zostavax, ACIP Recommendations: Live attenuated vaccines, such as Zostavax, contraindicated for severely immune-compromised - >20mg prednisone daily for >2 weeks, - Hemopoietic Stem Cell Tx - hematologic malignancies not in remission for >3 months, esp advanced Hodgkins disease, (ie cytotoxic therapy within past 3 months) - T cell immunodeficiency, including HIV+ pts with CD4<15% Zostavax probably safe with anti-tnf biologics but need more studies on the others (Zhang et al 2012) Heat killed zostavax effective in reducing zoster disease in transplant patients; (Hata A and Arvin A NEJM 2002); recent safety studies Immunize prior to chemotherapy (?14-30 days before) Tseng et al 2014 cf Shingrix GSK (Recombinant VZV ge + adjuvant ASO1B) not contraindicated and safe in immunecompromised (HSCT, HIV <15% CD4) 10
11 Licensure, availability and uptake worldwide USA: ACIP recommendation: immunize all immunocompetent persons>60 with one dose of Zostavax - over 25 million doses distributed since overall uptake: 10.0% in 2009, 14.4% in 2010, 2014:24% UK: Sept 2013: Funded immunization program: all people > 70 and catchup cohort >79 Australia: National Immunization Program funded for all i/c people >70 from Nov 2016; Catchup 71-79; Private market >50 since 2008 Zostavax: issues Low efficacy, especially in >80 Duration of efficacy -Need a booster, probably at 10 years Cost-effectiveness:? Commence age boosters OR at age 70 (cf France, Australia, UK) Safety in moderately immunecompromised pts needs better definition 11
12 Recombinant VZV/HSV glycoprotein + T cell adjuvant Pathogen Glycoprotein Antigen Adjuvants act as substitutes for natural T cell stimulants T cell stimulating adjuvant Systems Combinations of: - Classical adjuvants: aluminum salts, emulsion, liposomes - Immunostimulants: MPL, QS21, (CpG), dmpl QS21 12
13 Vaccines: recombinant proteins + T cell adjuvants Vaccine Antigen Adjuvant Antibody (neut) CD4 T cells Hepatitis B HBsAg ASO4 (dmpl) CD8 T cells HSV Glycoprotein D ASO4 (dmpl) Malaria RTS, S ASO1 (dmpl, QS21) Herpes zoster Glycoprotein E ASO1 (dmpl, QS21) ? CD4 T cell response to VZV ge Vaccine response rate 80+ YOA Vaccine response rates to HZ/su were also well-preserved with subject age. 13
14 ge-specific CD4 T cell responses after two doses of HZ/su Chlibek R. Heineman TC et al Vaccine, 2016, Phase III Trials of GSK Shingrix Placebo - RCT in Europe, USA, Australia Two doses IMI two months apart, 96% compliance ZoE-50: adults > 50 years, stratified in 10 year blocks, evaluable subjects -recently reported ZoE-70: adults >70 years to focus on PHN - headline results released by GSK 14
15 GSK Herpes Zoster (HZ/su) Vaccine Efficacy 100 Secondary Objectives Primary Objective % LL>25% >=70 >=60 OVERALL/>=50 15
16 ZoE-50 trial: reactogenicity and safety Overall: 84 % of vaccine recipients vs 38% of placebo recipients - severe: 17.0% of vaccine vs 3.2% of placebo recipients. Local/injection site Severe: 9.5% vs 0.5%, lasted on average 2 days Serious adverse events were similar in placebo and recipient No increased autoimmune diseases or exacerbations ZoE70 trial: efficacy against PHN 13,900 Adults >70: vaccine efficacy = 90% (95% CI 84-94) similar in and >80 efficacy against PHN: 89% (69-97) (Pooled) Adults>50 efficacy against PHN: 91% (76-98) Oct Data currently resubmitted to NEJM for publication (Cunningham, Lal..Heineman et al) 16
17 Shingrix: issues Two doses: likely compliance in real world setting (Hepatitis A: 65%) High reactogenicity Duration of efficacy to be determined (T cell immunogenicity plateaus for 2-6 years- promising) - long term followup trials about to commence Risk of auto-immunity with new adjuvants: needs long term post marketing surveillance Efficacy in severely immunecompromised: immunogenicity retained in patients undergoing allogeneic HSCT, phase III trial results available soon Conclusions Shingrix development and trialling confirms several scientific hypotheses: - vaccines consisting of a single pathogen protein and adjuvant(s) can be more efficacious than a live attenuated vaccine - such a combination may cut through immunosenescence = hope for other vaccines in older subjects - Pathogen/vaccine/adjuvant immunology is of increasing relevance for (rational) vaccine development 17
18 Acknowledgements Westmead Institute for Medical Research/ University of Sydney Herpesvirus Immunopathogenesis Min Kim Kirstie Bertram Allison Abendroth Kerrie J. Sandgren Naomi Truong David Booth Vaccine development & trials Janette Taylor Dominic Dwyer Paul Mac Seqirus Alicia Stein GSK Herpes zoster Trials: Tom Heineman (GSK) Himal Lal (GSK) Myron Levin (Denver) Adriana Weinberg International/Australian co-authors University of Melbourne David Jackson Weiguang Zeng Institut Cochin, Paris Anne Hosmalin UNSW Raina Macintyre Funded by; Australian National Health and Medical Research Council Vaccine trials: GSK Herpes zoster epidemiology: Seqirus SPARE SLIDES 18
19 Vaccine Efficacy (%) Subject- Years 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Estimated Vaccine Efficacy for 4 Years After Vaccination Vaccine= Placebo= Year 1 19,132 19,081 Year 2 18,827 18,679 Year 3 14,505 14,327 Year of Follow-up After Vaccination Year HZ BOI Incidence of PHN Incidence of HZ Comparison of durability of Zostavax in various models Li, X et al Vaccine, 2015,
20 Additional Effects on PHN (M Levin) Reduction in PHN even if Zoster developed Overall = 39% Age = 55% Age >80 = 26% Duration of pain shortened p = 0.03 Severity of pain decreased p = Is immune control of PHN (DRG) by Zostavax qualitatively different to that of Zoster rash (skin vs nerve)) Zostavax Concomitant use of Zostavax with: - influenza vaccine: Similar antibody responses and safety - pneumococcal vaccines: contradictory reports on risk of Zoster when immunized simultaneously 20
21 SPS Extension Study in year olds RDPC trial, USA, UK, Finland, 21,105 subjects HZ incidence decreased by 70% (54.1, 80.6) - HZ pain by 73% (52.7, 84.6) Similar efficacy to YOs, but lower incidence of of HZ and especially PHN in placebo group. Effect of second dose of Zostavax on VZV immune responses Three trials: 2 doses of Zostavax 6 wks apart vs placebo (n= 210. >60 years: Second dose did not boost VZV specific T cell (Elispot) or antibody (gp-elisa) responses> dose 1 (Vermeulen et al Vaccine 2011) - NB In SPS vaccine induced one log increase in antibody and T cell responses reduced zoster risk by 18% and 38% respectively Single vs 2 doses of vaccine either at 0,1 or 0,3 months (n=759, >70yo): No difference in antibody (gp-elisa GMT) responses up to 12 months later (Vesikari et al Hum Vacc 2013) Booster dose at age >70 (n=198): 1.5 geometric mean fold rise (GMFR) in antibody gp-elisa) from Day 1 to week 6 post immunization (Merck Clinical trials.gov 2013) Conclusions: Booster/second doses safe even if close together - Cannot overcome effect of age with two dose regime 21
22 Duration of protection of Zostavax Short term Persistence Substudy: Zostavax recipients; 6950 placebo recipients 89% of which accepted the offer of Zostavax; all participants followed for 4-7 years. Non significant decreases in VE for: zoster incidence (51 to 40%), PHN (67 to 60%) and BOI (61 to 50%). Limitations: subset (~50%) of original sites and gap in surveillance but no differences in subject characteristics to SPS Duration of protection of Zostavax Long term Persistence Substudy Open label Multicentre study, followed up 6867 vaccine recipients for 7-12 years. No unvaccinated concurrent control group so original SPS placebo recipients used as controls years post vaccination, VE = 21% for zoster, 35% for PHN and 37% for BOI - ie provides evidence for waning of efficacy but probably significant to 8 years when analysed annually. - Most experts viewing data believe a booster at 10 years will be necessary 22
23 Probability of Zoster 7/15/2016 Post-marketing studies of Zostavax efficacy 3 population based cohort studies: - Langan et al 2013: 5% of Medicare (>65yo) participants (n=29,785) : VE (zoster) = 48%; VE (PHN) = 59% Low vaccine uptake (3.9%) - Tseng et al 2011, Retrospective Kaiser Permanente study, Southern California: 303,044 members; VE= 55%, 63% for ophthalmic zoster and 65% for hospitalizations - Zhang et al 2012: Medicare beneficiaries with selected auto-immune diseases; VE= 39% Overall VE for incidence of zoster and PHN not significantly different to SPS Inactivated Zoster vaccine in Transplant patients Months 23
24 Zostavax in Immunecompromised Issues to Be Clarified Use in VZV+ Ill patients who expect immune suppression: Organ transplant Therapy for autoimmune disease (drugs or antibodies) Prior to chemotherapy Early HIV (>15% CD4) Post-licensure Zostavax vaccine safety studies 2 large post-licensure safety studies: Vaccine Safety Datalink Network (193,083 adults>50 yrs) and Kaiser- Permanente North California Study: Medically attended reactions 1-7 days post Zostavax were highest in the y.o age group (Tseng et al JIntern Med 2012; Baxter et al Vaccine 2012) - 83% local tenderness, swelling, erythema, 15% localised diffuse rash. No serious AEs early after vaccination - No serious AEs after a second dose of Zostavax within 1-3 months, nor as a 10 year booster (Levin et al, World Congress Geriatrics) - No increase in AEs when Zostavax administered to those with history of Zoster (15% of older adults) (Mills et al Vaccine 2010, Morrison et al JInfect Dis 2013) 24
25 Zostavax in Less Immunocompromised patients Post licensure studies: - Autoimmune diseases (arthritis and inflammatory bowel disease): 2 year followup VE (HZ) =39% (9,48%), safe - Population based cohort study of patients on immunosuppressive medication: VE (HZ) = 37% - Can use in asymptomatic HIV+ patients, but not if symptomatic or CD4 <15%; trial in progress (NB 6 fold decreased zoster risk on HAART) - Still inadequate data but Zostavax probably safe in mildmoderate immunecompromise: arthritis, SLE, IBD, chronic renal failure, diabetes, anti-tnf, prednisone <20mg daily Concomitant use of Zostavax with influenza and pneumococcal vaccines With Inactivated Influenza vaccine (n=380, >50 yo), sequential or simultaneous Similar antibody responses and safety (Kerzner et al, JAmGerSoc 2007) Pneumococcal Polysaccharide vaccine (23 valent) RDPC (n= 473); for immune response: simultaneous < sequential (McIntyre et al Hum Vacc 2010) - But Retrospective Cohort study (n=14,366) showed no increased risk of Zoster when immunized simultaneously (Tseng et al JAMA 2011) 25
26 RCF (per 100,000 PBMC) 7/15/2016 Tcell responses to VZV Decrease With Age >85 Age (years) CMI=cell-mediated immunity PBMC=peripheral blood mononuclear cell RCF=responder cell frequency Adapted from Levin M et al. Unpublished results. 26
Declarations. Herpes Zoster: The disease and the vaccines. Zoster: Latency and Reactivation. Take home message. Risk factors for Herpes Zoster
Herpes Zoster: The disease and the vaccines Tony Cunningham Centre for Virus Research The Westmead Institute for Medical Research Sydney, Australia Declarations Chair, Publications committee, GSK Shingrix
More informationProgress with Herpesvirus vaccines. Tony Cunningham Centre for Virus Research, Westmead Institute for Medical Research and University of Sydney
Progress with Herpesvirus vaccines Tony Cunningham Centre for Virus Research, Westmead Institute for Medical Research and University of Sydney Declarations Chair, Publications committee, GSK Shingrix ZoE50
More informationSubunit adjuvanted zoster vaccine: why the fuss?
Subunit adjuvanted zoster vaccine: why the fuss? Soren Gantt, MD PhD MPH Pediatric Infectious Diseases Vaccine Evaluation Center BC Children s Hospital University of British Columbia Disclosures Research
More informationZoster Vaccine for Older Adults
BC Centre for Disease Control IMMUNIZATION FORUM 29 Zoster Vaccine for Older Adults Michael N. Oxman, M.D. Professor of Medicine and Pathology University of California, San Diego VASDHS Staff Physician
More informationShingles: What s New to Know
This material was prepared by the New England Quality Innovation Network-Quality Improvement Organization (NE QIN-QIO), the Medicare Quality Improvement Organization for New England, under contract with
More informationAntigen Literature Review for the New Zealand National Immunisation Schedule, 2016: Herpes zoster
Antigen Literature Review for the New Zealand National Immunisation Schedule, 2016: Herpes zoster Prepared as part of a Ministry of Health contract for services by the Immunisation Advisory Centre Department
More informationZostavax vaccine: now fully subsidised
Dermatology Infections Older person s health Virology Zostavax vaccine: now fully subsidised Zostavax is a herpes zoster (shingles) vaccine that will become fully subsidised from 1 April, 2018 for people
More informationLes 2 articles qui peuvent changer votre pratique sur: Vaccination et biothérapies
Les 2 articles qui peuvent changer votre pratique sur: Vaccination et biothérapies VZV Epidemiology and Pathogenesis 98% adults Respiratory spread 1,000,000/year and increasing CMI continuously boosted
More informationHot Topics Adult Infectious Diseases 2018 Wayne Ghesquiere MD FRCPC
Hot Topics Adult Infectious Diseases 2018 Wayne Ghesquiere MD FRCPC Infectious Diseases Consultant Island Health Authority Clinical Assistant Prof of Med, UBC Victoria Faculty/Presenter Disclosure Wayne
More informationSCIENTIFIC DISCUSSION. London, Product name: Zostavax Procedure No. EMEA/H/C/000674/II/0003
SCIENTIFIC DISCUSSION London, 21.06.2007 Product name: Zostavax Procedure No. EMEA/H/C/000674/II/0003 SCIENTIFIC DISCUSSION 3.1. Introduction ZOSTAVAX is a live attenuated vaccine containing Varicella-zoster
More informationVaccines for Primary Care Pneumococcal, Shingles, Pertussis
Vaccines for Primary Care Pneumococcal, Shingles, Pertussis Devang Patel, M.D. Assistant Professor Chief of Service, MICU ID Service University of Maryland School of Medicine Pneumococcal Vaccine Pneumococcal
More informationzoster vaccine; re-vaccination; adjuvant; glycoprotein E; influenza vaccine.
The Journal of Infectious Diseases EDITORIAL COMMENTARY Clinical Usage of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su): Revaccination of Recipients of Live Attenuated Zoster Vaccine and Coadministration
More information9/12/2018. Zoster. Herpes Zoster (Shingles) Complications of Herpes Zoster
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Zoster September 2018 Chapter 22 Photographs and images included in this presentation are licensed solely
More informationVaccination against shingles for adults aged 70 and 79 years of age Q&A s for healthcare professionals
Vaccination against shingles for adults aged 70 and 79 years of age Q&A s for healthcare professionals Background In 2010, the Joint Committee on Vaccination and Immunisation (JCVI) 1 were asked by the
More informationUpdate on Adult Immunization Strategies: Understanding the Current Recommendations
Update on Adult Immunization Strategies: Understanding the Current Recommendations EDWARD A. DOMINGUEZ, MD, FACP, FIDSA Medical Director, Organ Transplant Infectious Diseases Methodist Dallas Medical Center,
More informationHERPES ZOSTER VACCINATION
HERPES ZOSTER VACCINATION Herpes Zoster (shingles) is a reactivation of the varicella zoster infection in some-one who has previously had varicella(chicken pox) disease Painful, unilateral, self-limiting
More informationShingrix (zoster vaccine recombinant, adjuvanted) NEW PRODUCT SLIDESHOW
Shingrix (zoster vaccine recombinant, adjuvanted) NEW PRODUCT SLIDESHOW Introduction Brand name: Shingrix Generic name: Zoster vaccine recombinant, adjuvanted Pharmacological class: Shingles vaccine Strength
More informationHerpes zoster vaccine in Korea
Review article CLINICAL EXPERIMENTAL VACCINE RESEARCH Herpes zoster vaccine in Korea Clin Exp Vaccine Res 2013;2:92-96 pissn 2287-3651 eissn 2287-366X Won Suk Choi Division of Infectious Diseases, Department
More informationDisclosures. I have no financial interests in immunizations discussed here. I may discuss off-label use of licensed vaccines
2/28/18 Disclosures I have no financial interests in immunizations discussed here I may discuss off-label use of licensed vaccines Herpes Zoster (HZ) and Postherpetic Neuralgia (PHN) epidemiology, United
More information11/17/2013 THE WHO, WHAT, WHEN, AND WHY OF ADULT VACCINATIONS. Pneumococcal Vaccines for Adults (PPV) Pneumococcal Vaccines
THE WHO, WHAT, WHEN, AND WHY OF ADULT VACCINATIONS CAROL A. KAUFFMAN, MD VA ANN ARBOR HEALTHCARE SYSTEM UNIVERSITY OF MICHIGAN Will discuss: bacterial vaccines made of toxoids or polysaccharide capsular
More informationPHN Tasmania Update March 2017
PHN Tasmania Update March 2017 Professor Robert Booy NCIRS, MBI, University of Sydney Acknowledgements: Professor Paul van Buynder Immunisation Coalition Overview of Immunisation Talk Varicella and Shingles
More informationDr Stewart Reid. General Practitioner Ropata Medical Centre Wellington
Dr Stewart Reid General Practitioner Ropata Medical Centre Wellington 7:15-8:10 Medicines New Zealand Breakfast Session Adult Vaccination The Poor Cousin Adult Vaccination The poor cousin Stewart Reid
More informationEmerging Issues in Reactivated Herpes Zoster Disease
Emerging Issues in Reactivated Herpes Zoster Disease Tim Hilderman, MD FRCPC 2018 Infection Prevention and Control Across the Continuum Friday, June 22 nd, 2018 DISCLOSURE STATEMENT Type of relationship
More informationUpdate on Adult Immunization Strategies: Understanding the Current Recommendations
Sunday CME Breakfast Update on Adult Immunization Strategies: Understanding the Current Recommendations Edward Dominguez, MD Medical Director, Organ Transplant Infectious Diseases Methodist Dallas Medical
More informationZOSTAVAX Zoster Virus Vaccine Live (Oka/Merck) Refrigerator stable
PRODUCT INFORMATION ZOSTAVAX Zoster Virus Vaccine Live (Oka/Merck) Refrigerator stable DESCRIPTION ZOSTAVAX is a lyophilized preparation of the Oka/Merck strain of live, attenuated varicella - zoster virus
More informationMarketVIEW: Herpes Zoster (adult) vaccines. Background. ****Published February 2014*** Product Name : MarketVIEW: Herpes Zoster (adult) vaccines
****Published February 2014*** MarketVIEW: Herpes Zoster (adult) vaccines Product Name : MarketVIEW: Herpes Zoster (adult) vaccines Description : Global vaccine commercial opportunity assessment Contents
More informationSession 1 Introduction to Vaccines and Basic Concepts
Module 8 Evaluating Immunological Correlates of Protection Session 1 Introduction to Vaccines and Basic Concepts Ivan S.F. Chan, Ph.D. Merck Research Laboratories 1 The Ten Greatest Public Health Achievements
More informationVaccine-preventable disease in adults How well are we doing at immunising older adults in Australia?
Shingles and adult immunisation in Australia: Using the new Zoster vaccination Associate Professor Michael Woodward AM University of Melbourne Austin Health Conflict of Interests Funded by Seqirus, Merck
More informationZOSTAVAX. CLINICAL TRIALS Evaluation of Clinical Efficacy Afforded by ZOSTAVAX
PRODUCT INFORMATION Zoster Virus Vaccine Live (Oka/Merck) Refrigerator stable DESCRIPTION is a lyophilized preparation of the Oka/Merck strain of live, attenuated varicella- zoster virus (VZV). The virus
More informationAn Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Update on the Use of Herpes Zoster Vaccine
An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Update on the Use of Herpes Zoster Vaccine TO PROMOTE AND PROTECT THE HEALTH OF CANADIANS THROUGH LEADERSHIP, PARTNERSHIP,
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL PRODUCT 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Registration No.: 1C 10/54 (NBC) Importer / Manufacturer: MSD (Thailand) Ltd. / Merck Sharp & Dohme Corp., West Point, Pennsylvania 19486, USA SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL
More information2013 Adult Immunization Update. David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle
2013 Adult Immunization Update David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Adult Immunization Update Pertussis Vaccine Influenza Vaccine Zoster
More informationSystematic Review Report: Efficacy and safety of adjuvanted herpes zoster subunit vaccine. Drug Assessment Working Group October 2018
Systematic Review Report: Efficacy and safety of adjuvanted herpes zoster subunit vaccine Drug Assessment Working Group October 2018 Table of Contents Page number Abbreviations/Glossary 3 Executive summary
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT ZOSTAVAX powder and solvent for suspension for injection shingles (herpes zoster) vaccine (live) 2. QUALITATIVE AND QUANTITATIVE
More informationWhat You Should Know about the 2018 Adult Immunization Schedule & New Recommendations
What You Should Know about the 2018 Adult Immunization Schedule & New Recommendations Adult Immunization Conference April 10, 2018 Susan M. Lett, M.D., MPH Medical Director Immunization Program Massachusetts
More informationSession 9. Correlate of Protection (CoP) (Plotkin and Gilbert, CID 2012)
Module 8 Evaluating Immunological Correlates of Protection Session 9 Validation Using Prentice Criteria and Causal Inference Framework, Design Considerations Ivan S.F. Chan, Ph.D. Merck Research Laboratories
More informationHIGH RISK IMMUNISATION
Overview HIGH RISK IMMUNISATION Dr. F Shaun Hosein Advanced Trainee, Public Health Medicine Sunshine Coast Public Health Unit Lecturer, University of Queensland Clinical Writer PHN Immunology Responses
More informationZOSTAVAX is indicated for immunisation of individuals 50 years of age or older.
1 PRODUCT NAME ZOSTAVAX Zoster Vaccine Live (Oka/Merck) Refrigerator stable 2 QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution with accompanying vial or pre-filled syringe of diluent, 1 dose
More informationPreventing Infections in the Era of Biologics
Preventing Infections in the Era of Biologics Deepali Kumar MD MSc FRCPC Immunocompromised Infectious Diseases Program University Health Network Toronto Disclosure Research Grants Roche, GSK Honoraria
More informationZOSTAVAX is indicated for immunisation of individuals 50 years of age or older.
1 PRODUCT NAME ZOSTAVAX Zoster Vaccine Live (Oka/Merck) Refrigerator stable 2 QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution with accompanying vial or pre-filled syringe of diluent, 1 dose
More informationWelcome to the CIC Education Hour
Welcome to the CIC Education Hour Shingles Vaccine 2.0: What you need to know Objectives Explain the clinical benefits and recommendations for administration of Shingrix, the new shingles vaccine Explain
More informationEvaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study
Evaluation of the effect of the herpes zoster vaccination 3 years after its introduction in England: a population-based study Gayatri Amirthalingam, Nick Andrews, Philip Keel, David Mullett, Ana Correa,
More informationVaccines in Immunocompromised hosts
Vaccines in Immunocompromised hosts Carlos del Rio, MD Emory Center for AIDS Research October 2013 Immunocompromised hosts Number has increased rapidly in the past decades Broad term that encompasses different
More informationJon Temte, MD/PhD Chair Wisconsin Council on Immunization Practices Professor of Family Medicine and Community Health
Jon Temte, MD/PhD Chair Wisconsin Council on Immunization Practices Professor of Family Medicine and Community Health University of Wisconsin School of Medicine and Public Health Grand Rounds September
More information22 Zoster (herpes zoster/ shingles)
22 (herpes zoster/ shingles) Key information Mode of transmission Period of communicability Burden of disease is a reactivation of the varicella zoster virus in someone who has previously had varicella
More informationBackground Rationale for resource
Slide 1 Background The Joint Committee on Vaccination and Immunisation 1 reviewed all the available medical, epidemiological and economic evidence as well as vaccine safety and efficacy relevant to offering
More informationAdult Vaccines in 2018: Where do we start?
Adult Vaccines in 2018: Where do we start? Jeff Goad, Pharm.D., MPH, FAPhA, FISTM Professor and Chair, Department of Pharmacy Practice Chapman University School of Pharmacy Annual Meeting San Francisco
More informationAUSTRA LIAN PRODUCT INFORMATION ZOSTAVAX Zoster Virus Vaccine Live (Oka/Merck) Refrigerator stable
AUSTRA LIAN PRODUCT INFORMATION ZOSTAVAX Zoster Virus Vaccine Live (Oka/Merck) Refrigerator stable 1 NAME OF THE MEDICINE Live varicella vaccine 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 0.65-mL
More informationWhat You Should Know about the 2018 Immunization Schedule & New Recommendations
What You Should Know about the 2018 Immunization Schedule & New Recommendations AAP Webinar April 19, 2018 Susan M. Lett, M.D., MPH Medical Director Immunization Program Massachusetts Department of Public
More informationShingles Prevention. Dr. JS Reid March 2014
Shingles Prevention Dr. JS Reid March 2014 1 Conflict of interest In the past I have received support for vaccine work, clinical trials, presentation of papers and conference attendance from NZ Ministry
More informationImmunization Update 2017
Immunization Update 2017 Tamara Sheffield, MD, MPA, MPH November 10, 2017 DISCLOSURE: I have no conflicts of interest to disclose I will be discussing off label use I will be discussing an unlicensed vaccine
More informationOREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS LIVE ZOSTER VACCINE
OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS LIVE ZOSTER VACCINE Revisions as of /4/10 Zostavax should not be given concomitantly with Pneumovax 3 due to reduced immune response to Zostavax.
More informationImmunizations: new and sometimes confusing recommendations MARK H. SAWYER, MD UCSD SCHOOL OF MEDICINE AND RADY CHILDREN S HOSPITAL SAN DIEGO
Immunizations: new and sometimes confusing recommendations MARK H. SAWYER, MD UCSD SCHOOL OF MEDICINE AND RADY CHILDREN S HOSPITAL SAN DIEGO Disclosures I have no financial disclosures related to this
More informationFor the use of a Registered Medical Practitioner or Hospital or Laboratory. SHINGLES (HERPES ZOSTER) VACCINE (LIVE) BP (Oka/Merck) ZOSTAVAX TM
For the use of a Registered Medical Practitioner or Hospital or Laboratory SHINGLES (HERPES ZOSTER) VACCINE (LIVE) BP (Oka/Merck) ZOSTAVAX TM ZOSTAVAX TM is a lyophilized preparation of the Oka/Merck strain
More informationVARICELLA. Dr Louise Cooley Royal Hobart Hospital
VARICELLA Dr Louise Cooley Royal Hobart Hospital Varicella Zoster Virus (VZV): The Basics Herpes virus Exclusively human infection Primary infection: varicella (chickenpox) Neurotropic, establishing latency
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT SHINGLES (HERPES ZOSTER) VACCINE (LIVE) BP (Oka/Merck) Powder and solvent for suspension for injection 0.65 ml Single Dose Vial of powder
More informationBackground Rationale for resource
Background The Joint Committee on Vaccination and Immunisation 1 reviewed all the available medical, epidemiological and economic evidence as well as vaccine safety and efficacy relevant to offering a
More informationUpdate on Immunizations H. Keipp Talbot, M.D., M.P.H.
Update on Immunizations H. Keipp Talbot, M.D., M.P.H. Vanderbilt University Medical Center 1 DISCLOSURES Financial Relationships with Relevant Commercial Interests Receive research funding from Sanofi
More informationZOSTAVAX Zoster Vaccine Live Lyophilized preparation for subcutaneous injection
9815603 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZOSTAVAX 1 safely and effectively. See full prescribing information for ZOSTAVAX. ZOSTAVAX
More informationVACCINATIONS AND INFLAMMATORY BOWEL DISEASE
VACCINATIONS AND INFLAMMATORY BOWEL DISEASE Bob Kizer MD Assistant Professor of Medicine Creighton University School of Medicine CONFLICTS OF INTEREST None 1 AN OPPORTUNITY FOR IMPROVEMENT IBD patients
More informationImmunization Update 2017 Adult Clinical Learning Day. Tamara Sheffield, MD, MPA, MPH
Immunization Update 2017 Adult Clinical Learning Day Tamara Sheffield, MD, MPA, MPH Highlighted Topics Influenza Vaccine Errors 2 Dose HPV Community protection Tdap in pregnancy Meningococcal Future Recs
More informationVaccinations for Adults
Case: Vaccinations for Adults Lisa Winston, MD University of California, San Francisco San Francisco General Hospital A 30-year old healthy woman comes for a routine visit. She is recently married and
More informationImmunization Update: Shingles, Mumps and Best Practice Oh my!!!
Immunization Update: Shingles, Mumps and Best Practice Oh my!!! Kevin W. Cleveland, PharmD, ANP Assistant Dean and Associate Professor Idaho State University College of Pharmacy February 2018 Disclosure
More informationImmunization across the age span: What s new and/or improved?
Immunization across the age span: What s new and/or improved? PICNet 2018 Educational Conference March 9 2018 Monika Naus MD MHSc FRCPC FACPM BC Centre for Disease Control School of Population and Public
More informationOpinion 15 October 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 15 October 2014 ZOSTAVAX, powder and solvent for suspension for injection in a pre-filled syringe B/1 glass vial 1
More informationSupplementary Materials. Determining the optimal vaccination schedule for herpes zoster: a cost-effectiveness analysis.
Supplementary Materials Determining the optimal vaccination schedule for herpes zoster: a cost-effectiveness analysis. Phuc Le, PhD, MPH and Michael B. Rothberg, MD, MPH. Long term efficacy of the live
More informationShingles Vaccine: FAQs
This Clinical Resource gives subscribers additional insight related to the Recommendations published in December 2017 ~ Resource #331201 Shingles Vaccine: FAQs The chart below addresses common clinical
More informationHerpes zoster results from reactivation
Herpes Zoster Pathogenesis and Cell-Mediated Immunity and Immunosenescence Michael N. Oxman, MD Herpes zoster, or shingles, is a localized disease characterized by unilateral radicular pain and a vesicular
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT ZOSTAVAX powder and solvent for suspension for injection ZOSTAVAX powder and solvent for suspension for injection in a pre-filled
More informationEvidence review on the immunogenicity, efficacy/effectiveness and safety of typhoid conjugate vaccines
Evidence review on the immunogenicity, efficacy/effectiveness and safety of typhoid conjugate vaccines SAGE meeting, Geneva, 17-19 October, 2017 Myron M. (Mike) Levine, MD, DTPH Grollman Distinguished
More informationClinical Policy Title: Zoster (shingles) vaccine
Clinical Policy Title: Zoster (shingles) vaccine Clinical Policy Number: 18.02.10 Effective Date: June 1, 2018 Initial Review Date: April 10, 2018 Most Recent Review Date: May 1, 2018 Next Review Date:
More informationWhat s New With Immunizations
What s New With Immunizations 2018 Annual Update COURTNEY A. ROBERTSON, PHARMD, BCPS CLINICAL ASSISTANT PROFESSOR UNIVERSITY OF LOUISIANA AT MONROE COLLEGE OF PHARMACY Disclosures No financial disclosures
More informationVaccination to protect against shingles - An update for registered healthcare practitioners
Vaccination to protect against shingles - An update for registered healthcare practitioners The programme from September 2016 and contraindications and precautions September 2016 NES and HPS accept no
More informationIn Case of Technical Difficulties
Shingles Vaccines: What You Need to Know Wednesday, December 6, 2017 12:00 PM ET In Case of Technical Difficulties If you hear an echo: Make sure you are only logged in once on your computer Select one
More informationHerpes Zoster and Meningococcal B Vaccine Updates
Herpes Zoster and Meningococcal B Vaccine Updates Michelle Miller, PharmD Assistant Professor of Clinical Sciences Bedrija Nikocevic, PharmD, BCACP Assistant Professor of Clinical Sciences Roosevelt University
More informationKenneth McCall, BSPharm, PharmD Associate Professor UNE
Kenneth McCall, BSPharm, PharmD Associate Professor UNE Objectives Discuss the gap between current rates and Healthy People 2020 goals for vaccinations. Categorize each of the CDC recommended flu vaccines
More informationShingles (herpes zoster) vaccine programme in Scotland for 2016/17
Annual report Shingles (herpes zoster) vaccine programme in Scotland for 216/17 Executive summary Shingles vaccine coverage for Scotland in the fourth year of the programme is presented in this report.
More informationOREGON PUBLIC HEALTH, DHS IMMUNIZATION PROTOCOL FOR PHARMACISTS. PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23-Valent Vaccine
OREGON PUBLIC HEALTH, DHS IMMUNIZATION PROTOCOL FOR PHARMACISTS PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23-Valent Vaccine Revisions as of 2/24/10 Pneumovax 23 should not be given concurrently with Zostavax
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (Zoster Vaccine Live) Suspension for
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION SHINGRIX. Herpes Zoster vaccine (non-live recombinant, AS01 B adjuvanted)
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION SHINGRIX Herpes Zoster vaccine (non-live recombinant, AS01 B adjuvanted) Suspension for injection Active immunizing agent GlaxoSmithKline Inc.
More informationKatherine Julian, MD July 1, Vaccines Generally Available in the U.S. U.S.
Katherine Julian, MD July 1, 2008 Vaccines Generally Available in the U.S. Vaccines Generally Available in the U.S. Vaccines for Special Populations Plague Tularemia Smallpox Anthrax Botulism Tuberculosis
More informationIt is crucial that practitioners refer to this updated chapter when administering the shingles vaccine.
In October Public Health England published a revised Green Book chapter for shingles and also health care professional FAQs. These revisions include changes to the contraindications and precautions sections.
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (Zoster Vaccine Live) Suspension for
More informationGuidelines for immunisation of children following treatment with high dose chemotherapy and Haematopoietic Stem Cell Transplantation (HSCT)
Guidelines for immunisation of children following treatment with high dose chemotherapy and Haematopoietic Stem Cell Transplantation (HSCT) Version 2.0 Approved by Haem / Onc Senior Clinical Management
More informationEMA guidelines on influenza vaccines
EMA guidelines on influenza vaccines High level hearing on the implementation of the Council Recommendation on seasonal influenza vaccination Presented by Manuela Mura on 30 April 2015 Scientific Officer
More informationImmunization Update 2018
Immunization Update 2018 Keri Hurley-Kim, PharmD, MPH Assistant Professor, Department of Pharmacy Practice West Coast University School of Pharmacy Conflicts of Interest Keri Hurley-Kim declares no conflicts
More informationU.S. Adult Vaccine Program Update: The Evolving Landscape. Laura P. Hurley, MD, MPH
U.S. Adult Vaccine Program Update: The Evolving Landscape Laura P. Hurley, MD, MPH Denver Health Objectives Discuss current status of adult vaccination in U.S. Review how the ACA might affect the adult
More informationPreventative Vaccines. Vaccines for Special Populations. Vaccinations for Adults: An Update. Vaccines Generally Available in the U.S.
Vaccinations for Adults: An Update Preventative Vaccines Need to be extremely safe Even greater issue as disease prevalence wanes or uncommon diseases targeted Lisa G. Winston, MD University of California,
More informationMoncef Slaoui. Chairman of Vaccines
Moncef Slaoui Chairman of Vaccines R&D programmes to deliver near-term growth with significant future opportunities and novel immunisation platforms 3 A new vaccine concept COPD 2 Longer term R&D Focus
More informationDownloaded from:
Forbes, HJ (2016) Understanding risk factors for herpes zoster and postherpetic neuralgia in UK primary care: investigations to inform vaccine policy. PhD thesis, London School of Hygiene & Tropical Medicine.
More informationVACCINATIONS FOR OLDER PATIENTS
VACCINATIONS FOR OLDER PATIENTS Douglas Fronzaglia II, DO, MS LECOM Institute for Successful Aging Geriatric and Internal Medicine 2/26/2019 Objectives Incorporate current CDC guidelines into your practice
More informationOTE. Shingrix : A New Herpes Zoster Subunit Vaccine. Shingrix : A New Herpes Zoster Subunit Vaccine
HAR Vol. 33, Issue 7 April 2018 M A N OTE Established 1985 Shingrix : A New Herpes Zoster Subunit Vaccine Amy Kernick, harmd Candidate in this issue Shingrix : A New Herpes Zoster Subunit Vaccine ersonalized
More informationHerpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort Study
against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort Study Sinéad M. Langan 1 *, Liam Smeeth 1, David J. Margolis 2, Sara L. Thomas 1 1 Department of Epidemiology
More informationVaccination to protect against shingles
Vaccination to protect against shingles - An update for registered healthcare practitioners The programme from September 2018 and contraindications and precautions Revised July 2018 NES and HPS accept
More informationVaccinations in MS. Consultant: Accordant, Acorda, Bayer, Biogen, Genentech/Roche, Genzyme/Sanofi, Mylan, Novartis, Serono, Teva
Vaccinations in MS Consultant: Accordant, Acorda, Bayer, Biogen, Genentech/Roche, Genzyme/Sanofi, Mylan, Novartis, Serono, Teva Research: Actelion, Genzyme/Sanofi, Novartis, Opexa 1 Immunobiological product
More informationUpdate on Immunizations and the Shingles Vaccine
Update on Immunizations and the Shingles Vaccine Conflict of Interest Disclosure I have no conflicts of interest to disclose. Sarah Scoular, PharmD., BCPS Annual Meeting 2018 Objectives 1. Describe the
More informationUPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES
DISCLOSURES UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES Nothing to disclose Kylie Mueller, Pharm.D., BCPS Clinical Specialist, Infectious Diseases Spartanburg Regional Medical Center LEARNING OBJECTIVES
More informationNothing to disclose. Vaccinations for Adults and Adolescents: An Update. Outline vaccines to be covered
Vaccinations for Adults and Adolescents: An Update Nothing to disclose. Lisa G. Winston, MD Professor of Medicine, University of California, San Francisco Vice Chief, Inpatient Medical Services and Hospital
More informationShingles Vaccine: FAQs
This Clinical Resource gives subscribers additional insight related to the Recommendations published in December 2017 ~ Resource #331201 Shingles Vaccine: FAQs The chart below addresses common clinical
More information